Getinge (OTCMKTS:GNGBY) Rating Increased to Strong-Buy at Zacks Research

Getinge (OTCMKTS:GNGBY) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

Getinge Stock Up 0.2%

Getinge stock opened at $23.96 on Tuesday. The firm has a market capitalization of $6.53 billion, a PE ratio of 22.82 and a beta of 0.96. The company’s 50-day moving average is $20.86 and its 200-day moving average is $21.33. Getinge has a fifty-two week low of $18.99 and a fifty-two week high of $24.67. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.32 and a quick ratio of 0.86.

Getinge (OTCMKTS:GNGBY) last issued its earnings results on Friday, July 17th. The company reported $0.38 earnings per share (EPS) for the quarter. Getinge had a net margin of 7.81% and a return on equity of 11.67%. The company had revenue of $894.87 million for the quarter. Sell-side analysts anticipate that Getinge will post 1.38 earnings per share for the current year.

Getinge Company Profile

Getinge AB is a global medical technology company that develops, manufactures and markets products and systems for hospitals and life sciences institutions. The company’s offerings focus on critical care, surgical workflows and infection control, aiming to improve clinical outcomes and operational efficiency. Getinge’s solutions support a range of applications from intensive care and cardiovascular treatments to sterile reprocessing of surgical instruments.

The company’s product portfolio includes sterilization and disinfection equipment, surgical tables and lights, ventilation systems, heart-lung machines and extracorporeal membrane oxygenation (ECMO) devices.